RPTXUnknownNano-Cap
Repare Therapeutics Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Repare Therapeutics Inc. (RPTX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are RPTX insiders buying or selling?
Repare Therapeutics Inc. insiders reported no open-market purchases or sales in the last 12 months. Since June 2020, Trabud has recorded 89 Form 4 filings for RPTX: 20 buys ($117.2M) and 69 sells ($115.8M).
Source: SEC EDGAR Form 4
Key Statistics (June 2020 – Mar 14, 2025)
Total Form 4 filings
89
SEC EDGAR
Insider filers
17
Insider buys (20)
$117.2M
Insider sells (69)
$115.8M
Insider sentiment
Net buyingNet insider flow of $1.4M in net buying since June 2020.
Recent RPTX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Mar 14, 2025 | Maria Koehler | EVP, CHIEF MEDICAL OFFICER | Sale | 3.6K | $1.14 | $4.1K | SEC ↗ |
| Mar 14, 2025 | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | Sale | 5.6K | $1.14 | $6.4K | SEC ↗ |
| Mar 14, 2025 | Steve Forte | EVP, CHIEF FINANCIAL OFFICER | Sale | 6.9K | $1.14 | $7.8K | SEC ↗ |
| Mar 14, 2025 | Lloyd Mitchell Segal | PRESIDENT AND CEO | Sale | 21.2K | $1.14 | $24.1K | SEC ↗ |
| Apr 2, 2024 | Lloyd Mitchell Segal | PRESIDENT AND CEO | Sale | 5.1K | $4.62 | $23.8K | SEC ↗ |
| Apr 2, 2024 | Steve Forte | EVP, CHIEF FINANCIAL OFFICER | Sale | 1.6K | $4.62 | $7.4K | SEC ↗ |
| Apr 2, 2024 | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | Sale | 860 | $4.65 | $4.0K | SEC ↗ |
| Apr 2, 2024 | Maria Koehler | EVP, CHIEF MEDICAL OFFICER | Sale | 800 | $4.65 | $3.7K | SEC ↗ |
| Mar 27, 2024 | Steve Forte | EVP, CHIEF FINANCIAL OFFICER | Sale | 2.5K | $4.67 | $11.6K | SEC ↗ |
| Mar 27, 2024 | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | Sale | 1.4K | $4.67 | $6.3K | SEC ↗ |
| Mar 27, 2024 | Maria Koehler | EVP, CHIEF MEDICAL OFFICER | Sale | 1.5K | $4.67 | $7.0K | SEC ↗ |
| Mar 27, 2024 | Lloyd Mitchell Segal | PRESIDENT AND CEO | Sale | 8.0K | $4.69 | $37.3K | SEC ↗ |
| Nov 17, 2023 | Mark N Lampert | 10% Owner | Purchase | 1.2M | $5.09 | $6.2M | SEC ↗ |
| Nov 3, 2023 | Mark N Lampert | 10% Owner | Purchase | 783.7K | $3.60 | $2.8M | SEC ↗ |
| Jun 9, 2023 | Michael Zinda | EVP, Chief Scientific Officer | Sale | 3.5K | $12.04 | $42.6K | SEC ↗ |
| Jun 7, 2023 | Michael Zinda | EVP, Chief Scientific Officer | Sale | 1.2K | $12.04 | $14.4K | SEC ↗ |
| Dec 13, 2022 | Davis Jerel | Director | Sale | 250.0K | $16.00 | $4.0M | SEC ↗ |
| Jun 15, 2022 | Mark N Lampert | 10% Owner | Purchase | 149.2K | $12.73 | $1.9M | SEC ↗ |
| Jun 7, 2022 | Versant Vantage I, L.P. | 10% Owner | Sale | 750.0K | $12.25 | $9.2M | SEC ↗ |
| Jun 7, 2022 | Versant Ventures V, LLC | 10% Owner | Sale | 750.0K | $12.25 | $9.2M | SEC ↗ |
| Jun 7, 2022 | Davis Jerel | Director, 10% Owner | Sale | 750.0K | $12.25 | $9.2M | SEC ↗ |
| Jun 6, 2022 | Mark N Lampert | 10% Owner | Purchase | 1.8M | $11.90 | $21.9M | SEC ↗ |
| May 20, 2022 | Mark N Lampert | 10% Owner | Purchase | 420.0K | $8.50 | $3.6M | SEC ↗ |
| Mar 16, 2022 | Michael Zinda | EVP, Chief Science Officer | Sale | 533 | $11.30 | $6.0K | SEC ↗ |
| Jan 21, 2022 | Mark N Lampert | 10% Owner | Purchase | 998.0K | $14.10 | $14.1M | SEC ↗ |
Showing the 25 most recent of 89 Form 4 filings for Repare Therapeutics Inc..
Most active RPTX insiders
- Ansbert Gadicke14 filings
- Todd Foley14 filings
- Michael Zinda13 filings
- Lloyd Mitchell Segal10 filings
- David P Bonita7 filings
Ask anything about RPTX insider activity
Use Trabud's AI agent to query Repare Therapeutics Inc.'s Form 4 history in plain English — "Show me RPTX CEO purchases this year" or compare it against any other ticker.
Open the AI agentRPTX insider trading FAQ
Are Repare Therapeutics Inc. insiders buying or selling?
Repare Therapeutics Inc. insiders reported no open-market purchases or sales in the last 12 months. Since June 2020, Trabud has recorded 89 Form 4 filings for RPTX: 20 buys ($117.2M) and 69 sells ($115.8M). Over the full record that is net buying of $1.4M.
How many insiders trade RPTX stock?
17 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Repare Therapeutics Inc.. The most recent filing was accepted on Mar 14, 2025.
Where does Trabud get RPTX insider trading data?
All RPTX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.